Identification of LKB1 mutation as a predictive biomarker for sensitivity to TOR kinase inhibitors

Details for Australian Patent Application No. 2011212927 (hide)

Owner Signal Pharmaceuticals, LLC

Inventors Sankar, Sabita; Chopra, Rajesh; Xu, Weiming; Ning, Yuhong; Xu, Shuichan

Agent HENRY HUGHES LTD

Pub. Number AU-A-2011212927

PCT Pub. Number WO2011/097333

Priority 61/301,150 03.02.10 US; 61/362,982 09.07.10 US

Filing date 3 February 2011

Wipo publication date 11 August 2011

International Classifications

A61K 31/497

Event Publications

23 August 2012 PCT application entered the National Phase

  PCT publication WO2011/097333 Priority application(s): WO2011/097333

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2011212928-Dihydropyridophthalazinone inhibitors of poly(ADP-ribose) polymerase (PARP) for use in treatment of diseases associated with a PTEN deficiency

2011212925-Multiple substituted fluoromethanes as selective and bioactive isosteres